2026年1月，辰欣药业因生产销售不符合标准的碳酸氢钠注射液被山东省药品监督管理局罚没合计312.5 万元，该事件源于2025年11月的处罚决定，并于2026年1月通过官方渠道披露。国家药监局此前已通报 该批次药品不合格，公司需持续关注整改措施及政策影响。 经济观察网根据当前公开信息，辰欣药业（603367）(股票代码：603367)近期有以下动态值得关注，基 于最新公告和市场数据整理。 监管情况 公司控股子公司山东辰欣佛都药业筹划在北京证券交易所上市的计划已于2024年审议通过，但后续进展 需关注官方公告。行业层面，医药板块受集采政策及创新药研发趋势影响，公司需平衡监管风险与增长 机会。 业绩经营情况 以上内容基于公开资料整理，不构成投资建议。 根据2025年第三季度报告，辰欣药业前三季度实现营业收入25.84亿元，同比下降13.94%；归母净利润 3.82亿元，同比下降4.05%。单季度来看，第三季度净利润同比上升19.61%，但扣非净利润下滑，反映 盈利质量波动。公司负债率为18.72%，毛利率保持55.08%。 资金动向 截至2026年2月6日，辰欣药业主力资金周度净流入1242.96万元，但单日资金 ...

Core Viewpoint - The announcement details the change of the sponsor representative for the ongoing supervision of the initial public offering (IPO) of Chenxin Pharmaceutical Co., Ltd. by Zhongtai Securities Co., Ltd. [1] Group 1: Change of Sponsor Representative - Zhongtai Securities has appointed Suo Jianpeng as the new sponsor representative to replace Zeng Liping, who has been reassigned to other responsibilities [1] - The ongoing supervision will continue until the obligations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange are fulfilled [1] Group 2: Acknowledgment of Contributions - The board of directors expresses gratitude for Zeng Liping's contributions during her tenure as the sponsor representative [2] Group 3: Background of New Representative - Suo Jianpeng is the Vice President of the Investment Banking Business Committee at Zhongtai Securities and has previously participated in various IPO projects [3]

Group 1 - The core point of the article is that Chenxin Pharmaceutical announced a change in its sponsor representatives, with Wang Fei and Suo Jianpeng appointed as the new continuous supervision representatives [2] - The continuous supervision period will last until the obligations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange are fulfilled [2]

证券代码：603367 证券简称：辰欣药业 公告编号：2026-004 辰欣药业股份有限公司 关于变更保荐代表人的公告 特此公告。 辰欣药业股份有限公司 董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辰欣药业股份有限公司（以下简称"辰欣药业"或"公司"）于 2026 年 2 月 10 日收到中泰证券股份有限公司（以下简称"中泰证券"）出具的《关于变更辰 欣药业股份有限公司首次公开发行股票并在主板上市项目持续督导保荐代表人的 报告》，具体情况如下： 中泰证券作为公司首次公开发行股票并在上海证券交易所主板上市项目的保 荐机构，原委派王飞先生和曾丽萍女士担任公司持续督导期的保荐代表人。现因 保荐代表人曾丽萍女士工作职责调整，不再担任辰欣药业的持续督导保荐代表人。 为保证公司持续督导工作的正常进行，根据《证券发行上市保荐业务管理办 法》等法规的规定，中泰证券决定委派索剑鹏先生（简历详见附件）接替原保荐 代表人曾丽萍女士担任本项目持续督导的保荐代表人，继续履行对本项目持续督 导的相关职责和义务。 本次保荐代表人变更后，公司持续 ...

Group 1 - China Resources Double Crane and Limin Pharmaceutical were fined 1 million and 3 million yuan respectively for producing sodium bicarbonate injection that failed to meet key quality indicators, specifically "visible foreign matter" and "pH value" [1][5] - The penalties were based on violations of Article 98 of the Drug Administration Law, which outlines strict regulations for drug production [1] - The specific batches involved were identified as 24120602 for China Resources Double Crane and K24110334 for Limin Pharmaceutical, with a total of 23,000 and 30,464 units respectively being deemed non-compliant [3][5] Group 2 - The fines imposed on Limin Pharmaceutical included the confiscation of all non-compliant products and a recovery of illegal gains amounting to 197.5 yuan [3] - For China Resources Double Crane, the total penalty reached 3.0317 million yuan, including the confiscation of illegal gains of 93,300 yuan, bringing the total to 3.125 million yuan [6] - Both companies were penalized following a notice from the National Medical Products Administration regarding 28 batches of non-compliant drugs, highlighting the regulatory scrutiny in the pharmaceutical industry [6]

Group 1 - The core viewpoint of the article is that Chenxin Pharmaceutical (603367.SH) has not exported to EU countries in the past two years while continuing to establish market connections with domestic and international clients [1] Group 2 - The company is actively building market relationships with both domestic and international customers [1] - There has been no export activity to EU countries in the last two years [1]

Core Viewpoint - The Shandong Provincial Drug Administration has imposed an administrative penalty on Chanshin Pharmaceutical Co., Ltd. for producing and selling sodium bicarbonate injection that does not meet national drug standards, resulting in a total fine of 3,125,018.20 yuan [1] Group 1: Regulatory Actions - Chanshin Pharmaceutical was fined 3,031,700 yuan and had 30,464 bottles of the non-compliant sodium bicarbonate injection confiscated due to violations of the Drug Administration Law [1] - The company was found to have produced a batch of sodium bicarbonate injection that failed to meet the required standards, specifically regarding visible foreign substances, and was included in a list of 28 batches of non-compliant drugs [1] Group 2: Company Overview - Chanshin Pharmaceutical, established in 1970 and listed on the Shanghai Stock Exchange in September 2017, is a large comprehensive pharmaceutical company located in Jining, Shandong Province [3] - The company operates five industrial parks covering nearly 2,000 acres, employs over 3,000 people, including more than 1,000 technical professionals, and has total assets of 7.5 billion yuan [3] - Chanshin Pharmaceutical offers over 400 specifications of various drug forms, including large-volume injections, small-volume injections, and raw materials, with a sales network spanning across China and over 50 countries and regions [3]

Group 1 - The company, Chenxin Pharmaceutical Co., Ltd., announced that shareholder Han Yanzhen holds 21,269,329 shares, representing 4.698% of the total share capital [2] - Han Yanzhen has released a pledge on 11,340,000 shares, which accounts for 53.32% of his total holdings and 2.50% of the company's total share capital [2] - After the release of the pledge, Han Yanzhen has no remaining pledged shares [2] Group 2 - As of the announcement date, Han Yanzhen and his concerted action party, Jiangsu Chenxin Tongtai Enterprise Management Co., Ltd., have a cumulative pledge of 0 shares, indicating no harm to the company's interests through non-operating fund occupation, illegal guarantees, or related transactions [3] - There are no subsequent pledge plans following the release of shares, and the company will fulfill its information disclosure obligations if future pledges occur [3] Group 3 - The company has received documentation related to the pledge release, including a fund reconciliation statement and a partial pledge release authorization letter from Han Yanzhen [4]

证券代码：603367 证券简称：辰欣药业 公告编号：2026-003 辰欣药业股份有限公司 关于股东股份解除质押的公告 1 | 剩余被质押股份数量 | 0 股 | | --- | --- | | 剩余被质押股份数量占其所持股份比例 | 0 | | 剩余被质押股份数量占公司总股本比例 | 0 | 附：据股东韩延振提供的《股票质押式回购交易部分解除质押委托书》显示，其此前于 2025 年 9 月 11 日解除 质押股份 2,010,000 股，占其当时持股总数的 7.32%，占当时公司总股本的 0.44%。 2、股东及其一致行动人累计质押情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截止本公告日，辰欣药业股份有限公司（以下简称"公司）股东韩延振持有公 司股份 21,269,329 股，占公司总股本比例为 4.698%。 韩延振本次解除质押股份 11,340,000 股，占其所持股份总数的 53.32%，占公 司总股本的 2.50%。本次股份解除质押后，剩余质押公司股份 0 股。 公司于 2026 年 1 ...

Group 1 - The National Medical Products Administration of China announced on January 6 that 28 batches of non-compliant drugs were identified, including sodium bicarbonate injection produced by Chenshin Pharmaceutical Co., Ltd., which failed due to visible foreign substances [1] - The visible foreign substances refer to insoluble materials that can be observed under specified visual conditions in injectable and ophthalmic solutions, typically with a particle size or length greater than 50 micrometers [2] Group 2 - Chenshin Pharmaceutical Co., Ltd. is a large comprehensive pharmaceutical enterprise engaged in research and development, production, and sales, listed on the Shanghai Stock Exchange main board in September 2017 [3] - The company is recognized as a national technology innovation demonstration enterprise and a national high-tech enterprise, and it serves as the vice president unit of the China Chemical Pharmaceutical Industry Association [3]